Cassava Sciences, Inc. (SAVAW)
- Previous Close
0.0300 - Open
0.1035 - Bid --
- Ask --
- Day's Range
0.0300 - 0.0300 - 52 Week Range
0.0200 - 11.0200 - Volume
2,510,746 - Avg. Volume
331,000 - Market Cap (intraday)
-- - Beta (5Y Monthly) -1.48
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
www.cassavasciences.com30
Full Time Employees
--
Fiscal Year Ends
--
Sector
--
Industry
Recent News: SAVAW
View More
Compare To: SAVAW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAVAW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.18%
Return on Equity (ttm)
-17.19%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.34M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
128.57M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-72.99M